Chong Kun Dang Holdings Corp. (KRX:001630)
South Korea
· Delayed Price · Currency is KRW 49,700
-500 (-1.00%)
Last updated: Apr 29, 2026, 3:00 PM KST
Chong Kun Dang Holdings Revenue
In the year 2025, Chong Kun Dang Holdings had annual revenue of 959.01B KRW with 0.13% growth. Chong Kun Dang Holdings had revenue of 235.99B in the quarter ending December 31, 2025, with 3.93% growth.
Revenue
959.01B
Revenue Growth
+0.13%
P/S Ratio
0.25
Revenue / Employee
25.92B
Employees
37
Market Cap
238.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 959.01B | 1.26B | 0.13% |
| Dec 31, 2024 | 957.75B | 77.97B | 8.86% |
| Dec 31, 2023 | 879.78B | -29.18B | -3.21% |
| Dec 31, 2022 | 908.96B | -17.01B | -1.84% |
| Dec 31, 2021 | 925.98B | 67.86B | 7.91% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Boditech Med | 162.09B |
| Hyundai Pharmaceutical | 108.14B |
| HLB Pharmaceutical | 205.58B |
| Daewon Pharmaceutical | 605.43B |
| Samjin Pharmaceuticals | 274.03B |
| Suheung | 722.31B |
| AptaBio Therapeutics | 3.70B |
| CMG Pharmaceutical | 105.23B |